Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07227298 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Symbiotic-Lung-20: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers

StatusRecruiting
PhasePhase 1/2
SponsorPfizer
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial sites expanded: 90 → 104 locations
  2. Trial sites reduced: 93 → 90 locations Trial sites expanded: 87 → 93 locations Show 1 more changeShow less
    • Trial sites expanded: 87 → 93 locations
  3. Study sites: 87 to 93 Interventions: PF-08046054/SGN-PDL1V (Biological), PF-08634404 (Biological), Sigvotatug Vedotin (Biological) to PF-08046054/SGN-PDL1V (Biological), PF-08634404 (Biological), Sigvotatug Vedotin (Biological) · Eligibility criteria expanded, about 13 words Show 2 more changesShow less
    • Interventions: PF-08046054/SGN-PDL1V (Biological), PF-08634404 (Biological), Sigvotatug Vedotin (Biological) to PF-08046054/SGN-PDL1V (Biological), PF-08634404 (Biological), Sigvotatug Vedotin (Biological)
    • Eligibility criteria expanded, about 13 words
  4. Trial sites expanded: 73 → 87 locations Interventions modified · Eligibility criteria expanded, about 14 wordsv8 Show 2 more changesShow less
    • Interventions modified
    • Eligibility criteria expanded, about 14 words

    See this version in full on ClinicalTrials.gov ↗

  5. Trial sites expanded: 55 → 73 locationsv7
  6. Trial sites expanded: 45 → 55 locationsv6
  7. Trial sites expanded: 32 → 45 locationsv5
  8. Trial sites expanded: 25 → 32 locationsv4
  9. Trial sites expanded: 5 → 25 locations Study title expanded, about 1 wordv3 Show 1 more changeShow less
    • Study title expanded, about 1 word

    See this version in full on ClinicalTrials.gov ↗

  10. Trial status: Not Yet Recruiting to Recruiting Study sites: 0 to 5 · Start date changed from estimate of Nov 17, 2025 to Jan 30, 2026v2 Show 2 more changesShow less
    • Study sites: 0 to 5
    • Start date changed from estimate of Nov 17, 2025 to Jan 30, 2026
  11. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study is being done to learn more about a new medicine called PF-08634404 and how it works when used with other cancer medicines in people who have advanced solid tumors. An advanced solid tumor is a type of cancer that has spread beyond its original location and cannot be removed by surgery or cured with standard treatments. To join in the study, participants must: * Be 18 years or older * Participants with advanced non-small cell lung cancer (NSCLC), a type of lung cancer that has spread to other parts of the body The study will look at: * Whether PF-08634404 is safe to use with other cancer medicines. * What side effects may happen. A side effect is anything the medicine does to your body that is not part of treating your disease. * Whether the combination of PF-08634404 and other cancer medicines can help treat solid tumors. The study has different parts, each testing PF-08634404 with a different cancer medicine: * Part A will test PF-08634404 with a medicine called sigvotatug vedotin. * Part B will test PF-08634404 with a medicine called PF-08046054/SGN-PDL1V Participants will receive the study medicines through an intravenous (IV) infusion (injected into the vein) at the study clinic. All treatments will take place at clinical trial sites, where trained medical staff will monitor participants during and after each visit.
Trial Details
NCT Number NCT07227298
Lead Sponsor Pfizer
Conditions Advanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Enrollment 162 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov